Oscar Health taps former Aetna leader as CEO

Technology-forward health insurance company Oscar Health has named Mark Bertolini as CEO, effective April 3.

Bertolini formerly served as CEO and chairman of insurance giant Aetna, which was acquired by CVS Health in 2018. As CEO, Bertolini will lead product and engineering, focusing on building out the company’s tech roadmap for the future. The company also announced Mario Schlosser, co-founder of Oscar Health, will transition to president of technology and report to Bertolini.

During his time at Aetna, Bertolini led the company’s transition from a traditional health insurer to a consumer-oriented healthcare company focused on integrated, local care. Prior to his time at Aetna, he also served in executive positions at Cigna, NYLCare Health Plans, and SelectCare, where he was president and CEO.

He most recently served as co-CEO of Bridgewater, and previously as co-chairman of the operating board. He remains an outside director on Bridgewater’s operating board of directors, and also serves as a director of Verizon Communications, Massachusetts Mutual Life Insurance Company, Thrive Global and the FIDELCO Guide Dog Foundation. He will also join the board of directors at Oscar Health.

“I have worked closely with Mark in his role as a strategic advisor to Oscar for the past 18 months and it’s become clear that we share a vision for the future of healthcare,” Schlosser said in a statement. “By pairing my passion in tech with Mark’s extensive expertise in building and scaling companies, we are well-positioned to continue to execute our strategy for profitability, set Oscar up for continued growth, and deliver enhanced value for our members and shareholders.”

The CEO appointment comes shortly after the company’s chief operating officer, Meghan Joyce, announced her resignation, effective April 10. New York-based Oscar Health was founded by Schlosser and Joshua Kushner and went public in 2021. It currently serves more than 1 million members. 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.